Ukukhutshwa kwesikhumba se-Atopic Dermatitis ngonyango olutsha

Ngaphezulu kweepesenti ze-50 zezigulane ezine-atopic dermatitis ephakathi ukuya kwi-atopic (AD) ubuncinane i-75 ipesenti yokunciphisa ubunzima besifo (EASI-75 *) kwiiveki ze-16 xa ifumana i-lebrikizumab monotherapy kwinkqubo ye-Advocate, i-Almirall SA (BME: ALM ) ibhengezwe namhlanje kwi-American Academy of Dermatology (AAD) iNtlanganiso yoNyaka. I-Lebrikizumab, i-IL-13 inhibitor yophando, nayo ikhokelele ekuphuculeni okunentsingiselo yeklinikhi kwi-itch kunye nezinye iziphumo ezibalulekileyo ezixelwe ngesigulana xa kuthelekiswa ne-placebo.              

"Iimpawu ze-atopic dermatitis ezinje ngokurhawuzelelwa, ulusu olomileyo, iintlungu eziqatha kunye nokudumba zithatha umthwalo onzima kubomi bezigulana nakwimpilo yazo. Izigulana zifuna amayeza anika iindlela zonyango ezisebenzayo nezinyamezelayo ezinokujongana nezo mpawu kunye nokuphucula umgangatho wobomi babo. I-Lebrikizumab yonyango olutsha kunye nokuthintela okuthe ngqo kwe-IL-13, umlamli ophakathi we-pathogenic kwi-AD. Ukuphumelela okubonwayo kwe-lebrikizumab kwezi zifundo kuqinisekisa amandla alo nyango lwenoveli, eya kuba yongezwa kakuhle kwi-atopic dermatitis armamentarium, "utshilo uProf. Dr. med. U-Diamant Thaçi, uMlawuli kwiZiko eliBanzi loNyango lwe-Inflammation kwiYunivesithi yaseLübeck eJamani, kunye nomphandi oyintloko we-Advocate 2 yolingo.

I-Lebrikizumab yi-antibody ye-monoclonal (mAb) ebophelela kwiprotheni ye-interleukin 13 (IL-13) enobudlelwane obuphezulu ukukhusela ngokukodwa ukubunjwa kwe-IL-13Rα1 / IL-4Rα (Uhlobo lwe-2 receptor) oluvimba ukubonakaliswa kwe-downstream nge-IL-13 indlela. I-1-5 IL-13 idlala indima ephambili kwi-Type 2 inflammation.6 Kwi-AD, i-IL-13 iphantsi kweempawu kunye neempawu ezibandakanya ukungasebenzi kakuhle kwesikhumba, ukubetha, ukusuleleka kunye neendawo ezinzima, ezinobunzima besikhumba.7

Kwi-Advocate 1, iipesenti ze-43 zezigulane ezifumana i-lebrikizumab ziphumelele isikhumba esicacileyo okanye esicacileyo (IGA) kwiiveki ze-16 xa kuthelekiswa neepesenti ze-13 zezigulane ezithatha indawo ye-placebo. Phakathi kwabo bafumana i-lebrikizumab, i-59 ipesenti iphumelele impendulo ye-EASI-75, xa kuthelekiswa neepesenti ze-16 kunye ne-placebo.

Kwi-Advocate 2, i-33 yepesenti yezigulane ezithatha i-lebrikizumab ziphumelele isikhumba esicacileyo okanye esicacileyo (IGA) kwiiveki ze-16, xa kuthelekiswa ne-11 ekhulwini yezigulane kwi-placebo. Phakathi kwabo bafumana i-lebrikizumab, i-51 ipesenti iphumelele impendulo ye-EASI-75, xa kuthelekiswa neepesenti ze-18 ezithatha indawo ye-placebo.

Kwisithuba seeveki ezine, izigulana ezifumana i-lebrikizumab ziye zafumana uphuculo olubonakalayo ekucoceni ulusu kunye nokurhawuzelelwa, kunye nokuphuculwa kokuphazamiseka kokurhawuzelelwa ebuthongweni, kunye nomgangatho wobomi, njengoko kulinganiswe ngamanqaku aphambili aphambili.

Iprofayili yokhuseleko lwexesha leeveki ze-16 yayihambelana nezifundo zangaphambili ze-lebrikizumab kwi-AD. Izigulane ezithatha i-lebrikizumab, xa kuthelekiswa ne-placebo, zichaze i-frequency ephantsi yeziganeko ezimbi kwi-ADvocate 1 (lebrikizumab: 45%, placebo: 52%) kunye ne-Advocate 2 (lebrikizumab: 53%, placebo: 66%). Uninzi lweziganeko ezimbi kuzo zonke izifundo ezibini zazinobulali okanye zimodareyitha ngobunzima kwaye azizange zikhokele ekuyekisweni konyango. Iziganeko ezimbi kakhulu eziqhelekileyo kwi-Advocate 1 kunye ne-2 kulabo base-lebrikizumab babeyi-conjunctivitis (7% kunye ne-8%, ngokulandelanayo), ukubanda okuqhelekileyo (nasopharyngitis) (4% kunye ne-5%, ngokulandelanayo) kunye nentloko (3% kunye ne-5%, ngokulandelanayo). ).

“Idatha entsha encumisayo evela kwiSigaba sesi-3 sophando lwe-monotherapy i-Advocate 1 kunye ne-Advocate yesi-2 enikezelwe kwiNtlanganiso yoNyaka ye-American Academy of Dermatology ibonisa ukuba i-lebrikizumab inamandla okuba lunyango oluphambili kwisizukulwana esitsha sebhayoloji. Izigulane zidinga iindlela ezintsha zonyango ezibonelela ngokusebenza okuphezulu kunye nokunyamezela okungcono. Esi siganeko sibalulekileyo siqhubela phambili ukuba siqhubeke nokugxila kwiinzame zethu kwenye yeemveliso eziphambili kwimibhobho yethu yamva kwaye siqhubele phambili ukuzibophelela kwethu ekuphuculeni umgangatho wobomi bezigulane ngonyango oluqalayo,” utshilo uKarl Ziegelbauer, Ph.D., IGosa lezeNzululwazi eliyiNtloko lase-Almirall SA.

Iinkcukacha zeziphumo zeeveki ezingama-52 ezivela kwi-Advocate 1 kunye ne-2, kunye nedatha yeeveki ezili-16 ezivela kwi-ADhere, isifundo seSigaba sesi-3 AD se-lebrikizumab nge-topical steroids, iya kubhengezwa kwiinyanga ezizayo. U-Almirall no-Eli Lilly kunye neNkampani baceba ukuhambisa iifayile kumagunya alawulayo kwihlabathi liphela ekupheleni kwe-2022 emva kokugqitywa kwezifundo ze-Advocate.

"Sijonge ekwabelaneni ngeziphumo zexesha elide ezivela kwi-Advocate 1 kunye ne-2 kulo nyaka, esikholelwa ukuba iya kugxininisa ngakumbi ukuba i-lebrikizumab inokubonelela ngesiqabu esifuneka kakhulu kubantu abasokolayo kwesi sifo singapheliyo, kwaye amaxesha amaninzi, isifo sobomi," utshilo uLotus. Mallbris, MD, Ph.D., usekela mongameli wehlabathi jikelele wophuhliso lwe-immunology kunye nemicimbi yezonyango eLilly.

I-Almirall inike imvume yamalungelo okuphuhlisa kunye nokuthengisa i-lebrikizumab kunyango lwezibonakaliso zedermatology, kuquka i-AD, eYurophu. U-Lilly unamalungelo akhethekileyo ophuhliso kunye norhwebo lwe-lebrikizumab e-United States kunye nehlabathi liphela ngaphandle kweYurophu.